Cypress Bioscience, Inc.

Watertown, MA 02172

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $0.0
First Award Date 03/15/95
Most Recent Award Date 09/01/97

Key Personnel

Last Name Name Awards Contact
Kim Byung K Kim 3

3 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/97 - 12/31/98

The long-term objective of the study is to develop a novel anti- platelet agent that may be useful to prevent arterial reocclusion and restenosis in the event of angioplasty therapy for cardiovascular disorder. We have previously demonstrated in the Phase study that a particular analogue of diadenosine tetraphosph...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/96 - 08/31/97

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/15/95 - 09/14/95

This Phase I application proposes to characterize three newly- developed chemical analogues of diadenosine-5',5'''-P1P4 tetraphosphate (AP4A) for their antiplatelet potency. These new AP4A analogues will be characterized with respect to (1) inhibition of ADP-induced platelet aggregation, (2) effect on platelet release rea...